New Releases from NCBI BookshelfDupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].​Dupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of severe chronic rhinosinusitis with nasal polyposis (CRSwNP) if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top